Results for:(39 found)
Sep 6, 2012 11:32AM on Top StocksBy MSN Money Partner

AK Steel is upgraded to 'buy,' and Dendreon is initiated with a 'buy.'

Aug 30, 2012 11:53AM on Top StocksBy MSN Money Partner

After FDA approval of its obesity drug, the biotech now awaits a DEA letter and the final decision from the EMA.

Tags: ARNA
Aug 9, 2012 3:02PM on Top StocksBy

An analyst says the weight-loss drug Qsymia can't live up to investors' expectations.

Jul 19, 2012 10:05AM on Top StocksBy Jim Cramer

Chartists, analysts and the public missed the boat on some key earnings. How else can we explain these market moves?

Jul 18, 2012 12:39PM on Top StocksBy MSN Money Partner

Stocks rise as housing starts climb more than expected.

Jul 18, 2012 11:28AM on Top StocksBy

Vivus becomes the second pharma this year approved to sell a weight-loss treatment.

Jul 11, 2012 10:15AM on Top StocksBy Jim Cramer

If a stock is up 500% in a straight line, that's a clue.

Jun 7, 2012 4:42PM on Top StocksBy Benzinga

Analysts are far from perfect. But sometimes their predictions are correct -- and can produce spectacular returns.



Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.


How to invest when the world is in chaos

As geopolitical tensions threaten to spin out of control, investors are wondering how best to position their portfolios for the global turmoil.



No more Dispatches; here's where to find market news

The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.